Table 1. 2017 Antiplatelet & anticoagulant recommendations after TAVI without alternate indication for oral anticoagulation.
| Guideline | Single antiplatelet therapy | Dual antiplatelet therapy | Vitamin K antagonist | NOAC |
|---|---|---|---|---|
| 2017: AHA/ACC | × | √ (IIb, C) | √ (IIb, B) | × |
| Duration | 6 months | 3 months | ||
| Comment | Low bleeding risk | |||
| 2017: ESC/EACTS | √ (IIb, C) | √ (IIa, C) | × | × |
| Duration | 3–6 months | |||
| Comment | High bleeding risk |
×, not recommended; √, recommended. TAVI, transcatheter aortic valve implantation; NOAC, novel oral anticoagulant; AHA, American Heart Association; ACC, American College of Cardiology; ESC, European Heart Association; EACTS, European Association for Cardio-Thoracic Surgery.